In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sarepta raises $505mm through upsized convertible note offering

Executive Summary

Sarepta Therapeutics Inc. (rare neuromuscular diseases) netted $505mm through the private placement of $570mm aggregate principal amount (including full exercise of a $95mm overallotment) of seven-year 1.5% convertible senior notes to qualified institutional purchasers, including the company's CEO, who purchased $2mm worth of shares. (Sarepta upsized the deal from its original intent to offer $375mm in notes with a $75mm overallotment.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies